Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/24/2022 | $5.00 | Buy | BTIG |
2/24/2022 | $50.00 | Buy | BTIG |
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinibThe FDA also provided positive feedback on the proposed key clinical and regulatory requirements of Oncternal's development program for zilovertamab in MCLGlobal registrational Study ZILO-301 is expected to be initiated in the second quarter of 2022Oncternal Therapeutics will host a conference call today at 4:30 p.m. ET to provide further details SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the d
10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily (BID) oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101 (NCT05917470). Overall, fifteen patients received ONCT-534 once daily (QD) in six dosing cohorts and six patients received ONCT-534 BID in two dosing cohorts. Based on a data cut off of September 30, 2024, the BID dosing schedule was w
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer, and ONCT-808, its ROR1-targeting autologous CAR T program for the treatment of patients with aggressive B-cell lymphoma, and to explore strategic alternatives. In the current study, interim Phase 1 results of ONCT-534 did not show clinically meaningful improvements of disease, including prostate-specific antigen (PSA) levels, in the 20 patients treated in eight dosing cohorts with vari
No dose-limiting toxicities or concerning side effects in our Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; 1200 mg cohort for ONCT-534 given orally once daily enrolled and treated; initial data readout expected in the third quarter of 2024Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma is open and enrolling patients; clinical data update expected in the fourth quarter of 2024Cash, cash equivalents and short-term investments totaled $21.4 million
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $19 price target.
Patients Receiving 1200 mg Daily Dose; Safety Review Committee Approved Higher Dose After Reviewing 600 mg Data; Initial Safety And Efficacy Update Expected In Q3 2024 Based On PSA Levels
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $19 price target.
SC 13G/A - Oncternal Therapeutics, Inc. (0001260990) (Subject)
SC 13G/A - Oncternal Therapeutics, Inc. (0001260990) (Subject)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management. The award will be made on May 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 5,000 shares of Oncternal common stock. The option will have a 10-year term
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal's President and CEO, James Breitmeyer, M.D., Ph.D. will join Oppenheimer Senior Research Biotech Analyst, Hartaj Singh and a prostate cancer Key Opinion Leader on Tuesday, March 19th, 2024 at 11:00 AM ET. Dr. Breitmeyer will discuss the development of Oncternal's novel dual-acting androgen receptor inhibitor, ONCT-534, the ongoing Phase 1/2 clinical trial ONC
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science. The award will be made on February 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 4,500 shares of Oncternal common stock. The option will have a
BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $5.00
BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $50.00
Oppenheimer initiated coverage of Oncternal Therapeutics with a rating of Outperform and set a new price target of $14.00